Group 1 - The stock of Brilliant Tomorrow (01351) was transferred from First Shanghai Securities to Fuzhou Securities (International) on September 16, with a market value of HKD 91.3633 million, accounting for 35.83% of the total [1] - Trading of Brilliant Tomorrow's shares has been suspended on the Hong Kong Stock Exchange since 9:00 AM on September 15, 2025, pending an announcement regarding insider information in accordance with the Hong Kong Code on Takeovers and Mergers [1]

Group 1 - The latest data from the Hong Kong Stock Exchange shows that on September 12, shareholders of Boyaa Interactive (00434) deposited shares into First Shanghai Securities Company, with a market value of HKD 462 million, accounting for 8.44% [1] - On the same day, Boyaa Interactive announced the issuance of 59.973 million shares according to a placement agreement dated August 21, 2025, scheduled for September 12, 2025 [1]

Group 1 - The core point of the article is that Boyaa Interactive (00434) has deposited shares worth HKD 462 million into First Shanghai Securities, representing 8.44% of the total shares [1] - On the same day, Boyaa Interactive announced the issuance of 59.973 million shares according to a placement agreement dated August 21, 2025, with the issuance date set for September 12, 2025 [1]

Core Viewpoint - First Shanghai maintains a "Buy" rating for Shenzhou International (02313) with a target price of HKD 79.80, highlighting the company's strong performance despite fluctuations in the sports brand and macroeconomic environment [1] Group 1: Financial Performance - In the first half of 2025, the company's revenue increased by 15.3% to RMB 14.97 billion, driven primarily by volume growth, while prices in USD decreased by 0.8% [2] - Gross margin declined by 1.9 percentage points to 27.1%, mainly due to increased employee compensation in the second half of the previous year [2] - The company recorded a net profit attributable to shareholders growth of 8.4% to RMB 3.18 billion, with an interim dividend of HKD 1.38, maintaining a stable payout ratio of 60% [2] Group 2: Product and Market Performance - The sports category showed stable growth, with product segments recording changes of +9.9% for sports, +37.4% for leisure, +4.1% for underwear, and +6.0% for others [3] - Growth in the sports category was primarily driven by demand in the US and European markets, while the leisure category benefited from increased demand in Japan, Europe, and other regions [3] - Regional performance showed increases of +19.9% in Europe, +35.8% in the US, +18.1% in Japan, +18.7% in other regions, and a slight decline of -2.1% in the domestic market [3] Group 3: Operational Insights - The company expects high single-digit growth in volume in the second half of the year, with an improvement in gross margin due to faster growth in sports products [4] - In terms of capacity, the company has recruited 4,000 employees in Cambodia in the first half of the year, with a total recruitment target of 6,000 for the year [4] - The acquisition of a factory in Vietnam is expected to increase daily production capacity by 200-300 tons, with minimal impact from tariffs as the company will maintain the FOB model [4]

Core Viewpoint - First Shanghai maintains a "Buy" rating for Shenzhou International (02313) with a target price of HKD 79.80, highlighting the company's strong performance despite fluctuations in the sports brand and macroeconomic environment [1] Group 1: Financial Performance - For the first half of 2025, the company's revenue increased by 15.3% to RMB 14.97 billion, driven primarily by volume growth, while prices in USD decreased by 0.8% [1] - Gross margin declined by 1.9 percentage points to 27.1%, mainly due to increased employee compensation in the second half of the previous year [1] - The company recorded a net profit attributable to shareholders growth of 8.4% to RMB 3.18 billion, with overall revenue growth exceeding expectations [1] Group 2: Product and Market Performance - The sports category grew by 9.9%, while the leisure category saw a significant increase of 37.4%, driven by demand in the US, Europe, and Japan [2] - Regional performance showed Europe, the US, Japan, and other regions growing by 19.9%, 35.8%, 18.1%, and 18.7% respectively, while the domestic market declined by 2.1% [2] - The growth of major clients like Nike, Adidas, Uniqlo, and Puma was 6.0%, 28.2%, 27.4%, and 14.7% respectively, with their combined market share increasing by 2.7 percentage points to 82.1% [2] Group 3: Future Outlook and Capacity - The company expects high single-digit growth in volume for the second half of the year, with an improvement in gross margin due to faster growth in sports products [3] - In terms of capacity, the company has recruited 4,000 employees in Cambodia in the first half and plans to hire a total of 6,000 by year-end, while the acquisition of a factory in Vietnam will increase daily capacity by 200-300 tons [3] - Capital expenditure for the first half was RMB 1.5 billion, with an estimated total of around RMB 2.3 billion for the year [3]

Core Viewpoint - The report maintains a "Buy" rating for Bruker (00325), projecting Non-GAAP net profits of 725 million, 998 million, and 1.268 billion yuan for 2025-2027, with a target price of 123.6 HKD, indicating a potential upside of 30.1% from the current stock price [1] Revenue Performance - In the first half of 2025, the company achieved revenue of 1.348 billion yuan, a year-on-year increase of 27.9%, with a net profit of 297 million yuan, returning to profitability [1] - Adjusted net profit reached 320 million yuan, up 9.6% year-on-year, with an adjusted net profit margin of 23.9%, down 4.0 percentage points [1] Product Category Growth - The sales revenue of building block role-playing toys was 1.325 billion yuan, up 29.5% year-on-year, with sales volume increasing by 96.8% to 111 million units, while the average price decreased by 33.5% to 12.0 yuan [1] - The sales of building block toys declined by 45.5% year-on-year, with sales volume down 42.9% to 100 thousand units [1] - Other products generated revenue of 330 thousand yuan, a year-on-year increase of 111.5% [1] Channel Performance - Offline sales through distributors reached 1.212 billion yuan, up 26.5% year-on-year, accounting for 90.6% of total sales [2] - Online sales amounted to 108 million yuan, a year-on-year increase of 44.6%, representing 8.1% of total sales, driven by increased sales among consumers aged 16 and above [2] Geographic Revenue Growth - Domestic revenue was 1.226 billion yuan, up 18.5% year-on-year, while overseas revenue surged to 111 million yuan, a staggering increase of 898.6%, accounting for 8.3% of total revenue [3] - Revenue from Asia (excluding China), North America, and other overseas regions grew by 652.5%, 2135.9%, and 594.7% respectively [3] IP Structure and User Demographics - The company is diversifying its IP matrix to reduce reliance on single IPs, with the top four IPs contributing over 10% each, totaling 83.1% of revenue, compared to 92.3% for the top three IPs last year [4] - The revenue contribution from products targeting consumers aged 16 and above increased to 14.8%, up 4.4 percentage points year-on-year, while the core revenue source remains products for ages 6-16, accounting for 82.6% [4] Profitability and Investment - The gross profit margin for the first half of 2025 was 48.4%, down 4.5 percentage points year-on-year, attributed to a higher proportion of lower-margin new products and increased depreciation from more molds [5] - Sales, R&D, and management expense ratios were 13.2%, 9.6%, and 3.5% respectively, with sales expenses rising due to increased marketing for new products and a growing sales team [5] - R&D expenses increased significantly due to a rise in personnel, with the R&D team growing by 81.0% to 599 members [5]

Core Viewpoint - The company maintains a "buy" rating for Bruker (00325) with a target price of HKD 123.6, indicating a potential upside of 30.1% from the current stock price, based on projected Non-GAAP net profits of 725 million, 998 million, and 1.268 billion for the years 2025-2027 [1] Revenue and Profitability - In the first half of 2025, the company achieved revenue of 1.348 billion, a year-on-year increase of 27.9%, with a net profit of 297 million, turning positive compared to the previous year [1] - Adjusted net profit reached 320 million, reflecting a 9.6% increase year-on-year, with an adjusted net profit margin of 23.9%, down 4.0 percentage points from the previous year [1] Product Performance - The sales revenue for building block toys decreased by 45.5% to 13 million, with a volume drop of 42.9% to 100,000 units, while the sales of character-based toys increased by 29.5% to 1.325 billion, with a significant volume increase of 96.8% to 111 million units [2] - The average price of character-based toys fell by 33.5% to 12.0, primarily due to the introduction of a new budget product priced at 9.9, which contributed 216 million in revenue [2] Sales Channels - Offline sales accounted for 90.6% of total sales, reaching 1.212 billion, a 26.5% increase year-on-year, while online sales grew by 44.6% to 108 million, representing 8.1% of total sales [3] Geographic Performance - Domestic revenue was 1.226 billion, up 18.5% year-on-year, while overseas revenue surged by 898.6% to 111 million, now accounting for 8.3% of total revenue [4] - Revenue from Asia (excluding China), North America, and other overseas regions saw significant growth, with increases of 652.5%, 2135.9%, and 594.7% respectively [4] IP and User Demographics - The company has diversified its IP structure, reducing reliance on single IPs, with the top four IPs contributing over 10% each, totaling 83.1% of revenue [5] - The revenue share from products targeting consumers aged 16 and above increased to 14.8%, while the core revenue source remains products for ages 6-16, accounting for 82.6% [5] Cost Structure and Investment - The gross margin for the first half of 2025 was 48.4%, down 4.5 percentage points, attributed to changes in product mix and increased depreciation from new molds [6] - Sales, R&D, and management expense ratios were 13.2%, 9.6%, and 3.5% respectively, with increases in sales and R&D expenses due to new product promotions and a growing R&D team [6]

Core Viewpoint - First Shanghai maintains a "buy" rating for Kangchen Pharmaceutical (01681) and adjusts the profit forecast for 2025-2027, setting a target price of HKD 25.20, indicating a potential upside of 59.50% from the current price [1] Financial Performance - Kangchen Pharmaceutical reported a revenue of RMB 1.569 billion for the first half of 2025, representing a year-on-year growth of 23.7% [2] - Gross profit increased by approximately 27.6% to RMB 1.209 billion, with a gross margin of 77.1%, up 2.4 percentage points from the same period in 2024, mainly due to a decrease in raw material prices [2] - Shareholders' profit attributable to the company was approximately RMB 498 million, a year-on-year increase of 24.6% [2] - The company continues its high dividend policy, proposing an interim dividend of HKD 0.33 per share, with a payout ratio exceeding 51% [2] Product and Business Development - The sales revenue of nephrology drugs reached approximately RMB 1.131 billion, a year-on-year increase of about 28.0%, driven by the core product, Uremia Qing granules, which maintains a leading position in the modern Chinese medicine category for kidney diseases [3] - Sales revenue from pediatric and women's drugs was approximately RMB 172 million, up about 17.5% year-on-year, with the unique oral iron supplement, Yuanlikang, entering the national essential drug and medical insurance catalog [3] - The medical imaging contrast agent series generated sales of approximately RMB 95 million, a year-on-year increase of about 22.0% [3] - The company has launched new CT contrast agents and has a rich pipeline of products under development [3] Market Position and Competitive Advantage - Uremia Qing granules are the flagship product of Kangchen Pharmaceutical, holding a leading position in the kidney disease Chinese medicine market, with a significant target market due to the high prevalence of chronic kidney disease (CKD) in China [4] - The product is the first kidney disease Chinese medicine to complete evidence-based medical research and has received strong recommendations in multiple clinical guidelines [4] - Despite the expiration of the product's patent in 2024, the complexity of its compound formulation and stringent drug approval processes are expected to maintain high market barriers and a concentrated competitive landscape [5]

Core Viewpoint - First Shanghai maintains a "buy" rating for Kangchen Pharmaceutical (01681) and adjusts the profit forecast for 2025-2027, setting a target price of HKD 25.20, indicating a potential upside of 59.50% from the current price [1] Group 1: Overall Performance - Kangchen Pharmaceutical demonstrated strong performance in the first half of 2025, with revenue reaching RMB 1.569 billion, a year-on-year increase of 23.7% [1] - Gross profit grew approximately 27.6% to RMB 1.209 billion, with a gross margin of 77.1%, up 2.4 percentage points from the same period in 2024, attributed to lower raw material costs [1] - Shareholder profit attributable to the company was approximately RMB 498 million, a year-on-year increase of 24.6%, with a proposed interim dividend of HKD 0.33 per share, resulting in a payout ratio exceeding 51% [1] Group 2: Core Product Growth - Revenue from nephrology drugs reached approximately RMB 1.131 billion, a year-on-year increase of about 28.0%, driven by the core product, Uremia Qing granules, which maintains a leading position in the modern Chinese medicine category for kidney disease [2] - Revenue from pediatric and women's health drugs was approximately RMB 172 million, a year-on-year increase of about 17.5%, with the unique oral iron supplement, Yuanlikang, gaining market share after the removal of reimbursement restrictions [2] - Sales of medical imaging contrast agents reached approximately RMB 95 million, a year-on-year increase of about 22.0%, with multiple new products launched and a rich pipeline of products under development [2] Group 3: Leading Position in Nephrology - Uremia Qing granules are the flagship product of Kangchen Pharmaceutical, holding a leading position in the kidney disease Chinese medicine market, with a unique competitive advantage [3] - The product is primarily used for chronic kidney disease (CKD), effectively lowering serum creatinine levels and delaying the progression of CKD, with a high safety profile [3] - The prevalence of CKD in Chinese adults is as high as 8.2%, with an estimated patient population exceeding 120 million, indicating a substantial target market [3] Group 4: Market Dynamics and Future Outlook - Uremia Qing granules have a broad range of indications and high clinical application frequency, supported by a strong sales and public relations team [4] - The product is included in the medical insurance directory, making it affordable, and the company has adopted a "price for volume" strategy to consolidate and enhance market share [4] - Despite the expiration of the product's patent in 2024, the complexity of its compound formulation and stringent drug approval processes are expected to maintain high market barriers and a concentrated competitive landscape [4]

Core Viewpoint - First Shanghai maintains a "buy" rating for NetDragon (00777), highlighting the stability of the company's gaming business and the potential of its education business market space [1] Group 1: 2025 Mid-Year Performance - NetDragon is projected to achieve revenue of 2.38 billion RMB in the first half of 2025, with a gross profit of 1.7 billion RMB, reflecting a gross margin increase of 2.9 percentage points to 69.5% year-on-year [2] - Operating expenses are expected to be 1.35 billion RMB, a decrease of 15.6% year-on-year, indicating the effectiveness of the company's cost optimization and efficiency improvement measures [2] - The company has a solid financial position with net cash of approximately 1.5 billion RMB and holds 12,000 Ethereum as digital asset reserves [2] - A mid-term dividend of 0.5 HKD per share has been announced, with a commitment to return at least 600 million HKD to shareholders through dividends and share buybacks over the next year [2] Group 2: Gaming Business - In the first half of 2025, the gaming and other businesses generated revenue of 1.74 billion RMB, showing signs of stabilization compared to the second half of 2024 [3] - The Monthly Active Users (MAU) of "Magic Domain" increased by 11% year-on-year, with mobile revenue also showing a quarter-on-quarter increase, indicating improved user engagement and retention [3] - The operating profit margin for the gaming business has rebounded to 28.8%, nearing historical normal levels [3] - Upcoming product launches include "Code MY" which began small-scale testing in August, and plans to expand "Magic Domain" and "Code Alpha" into multiple overseas markets [3] Group 3: Education Business - The Mynd.ai business generated revenue of 640 million RMB in the first half of 2025 [4] - In response to challenges from reduced global education technology spending, the company will continue to pursue cost optimization [4] - Despite weak performance in traditional markets in Europe and the US, the company is actively exploring emerging markets for new growth opportunities [4] - While short-term pressures from fluctuations in overseas education budgets remain, the long-term logic of increasing global education digital penetration remains unchanged [4]